37.14 0.00 (0.00%)
After hours: 5:37PM EDT
|Bid||36.63 x 1000|
|Ask||37.25 x 800|
|Day's Range||36.73 - 37.38|
|52 Week Range||31.43 - 48.25|
|Beta (5Y Monthly)||0.46|
|PE Ratio (TTM)||37.44|
|Forward Dividend & Yield||2.40 (6.36%)|
|Ex-Dividend Date||Feb 19, 2020|
|1y Target Est||N/A|
The treatment, Nucala, was tested in patients with a form of chronic rhinosinusitis who had a history of previous surgery and needed further surgery due to severe symptoms or worsening of the condition, the British drugmaker said. The study met both main goals and showed that Nucala(mepolizumab), which is administered using a pre-filled syringe, when added to standard of care led to statistically significant improvements in both the size of nasal polyps and in nasal obstruction compared to the placebo arm, GlaxoSmithKline said.
A mix of legacy drugmakers and small startups have stepped forward with plans to develop vaccines or treatments that target the infection caused by the novel coronavirus.
(Bloomberg Opinion) -- If we want a vaccine or drug treatment to stop coronavirus, the government should ignore those complaining about drug-company profits and commit to a huge reward that encourages more businesses to develop one. It wouldn’t just save lives; it could save the global economy. The coronavirus could cost the U.S. $1.5 trillion in annual economic output, or $125 billion every month — and that’s a conservative estimate. The losses for the entire world economy will be four to five times larger. And these economic costs will be dwarfed by the human costs of illness and death. Absent a vaccine or treatment, this pandemic will likely be with us for more than a year. Speeding the development of vaccines and effective drug therapies by vastly increasing the rewards for businesses would decisively limit the economic damage. Based on the economic losses in the U.S. alone, the government should be willing to spend at least an additional $62.5 billion to spur Covid-19 research and development. Even if that shortened the crisis by just two weeks, it would be a bargain. Research teams at large pharma companies such as Roche, Eli Lilly, Sanofi Pasteur and Takeda, and smaller biotech firms such as BioNTech, are racing to develop a vaccine. But these firms stand to capture only a small fraction of the large economic benefit that will accrue to society when they successfully produce a vaccine or therapy. Developers will likely be pressured to offer a future vaccine at a low price. Even now, there have been calls to sharply limit future profits from such a vaccine. The result is significant underinvestment in the development of vaccines that will likely have large social benefits. Here is a simple way to see this. U.S. spending on all pharmaceutical R&D in 2020 was projected to be $80 billion — equivalent to three weeks of the annual U.S. economic output loss — with only a small fraction of this directed toward infectious diseases. In 1967, 26 pharmaceutical companies produced vaccines; by 1980, 17 did; only four — GlaxoSmithKline, Merck, Pfizer and Sanofi Pasteur — undertake significant production today. This is not surprising. Developing a vaccine requires $500 million to $1 billion in investment, recent estimates suggest, while only 7% of projects result in a vaccine. As a result, even today, with the pandemic raging, many small biotech firms are watching from the sidelines. Those working on vaccines rely on money from foundations and government initiatives. Two of the most promising developers of a Covid-19 vaccine, Inovio and Moderna, are funded by the Coalition for Epidemic Preparedness Innovations (Cepi), an alliance of charities and governments. The U.S. government, perhaps working with others, should guarantee a significant financial payment to whoever first develops a vaccine. One way to do this would be to commit to a high price for each administered dose of an effective vaccine or treatment therapy. As an example, if the U.S. government were to promise a price of $190 per administered dose to the developers, spending a maximum of $62.5 billion to vaccinate or treat all Americans, then society would have earned back its investment even if this only sped up the development by two weeks. The vaccine should also be made available at marginal cost to developing countries.The government could further stimulate collaboration by committing to large awards for successful clinical trials, provided that the research is fully disclosed. If the European Union were to make a similar commitment to this price per administered dose, the total incentives could be strengthened by another $100 billion. While creating vaccines always takes time, experts in the field have learned from previous episodes that there can be major bottlenecks in vaccine development and manufacturing. Once developed, the supply is likely to fall short of demand for a long period. Additional financial resources can relieve these production bottlenecks. We are not asking the U.S. government, or any other government, to pick winners. We are asking the government to make an ironclad commitment right now, backed by legislation, to reward those companies that successfully lead the fight against Covid-19 and future outbreaks.This column does not necessarily reflect the opinion of Bloomberg LP and its owners.Hanno Lustig is a professor of finance at Stanford University. Jeffrey Zwiebel is a professor of finance at Stanford University. For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Pfizer stock could see some gains in 2020 if it makes progress on a coronavirus vaccine with BioNTech. But its Upjohn merger with Mylan is now delayed. Is Pfizer stock a buy now?
Shares of Dynavax Technologies Corp. gained 10% in trading on Thursday after the company said it's making its adjuvant technology available to companies developing COVID-19 vaccines through a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI), a not-for-profit organization in Oslo that has provided funding to a handful of vaccine developers in this pandemic. Dynavax's adjuvant technology can help provide an increased immune response to a vaccine; the biopharmaceutical company is also working with the University of Queensland, Australia, on vaccine development through a CEPI deal. GlaxoSmithKline , which is lending its adjuvant technology to COVID-19 vaccine development plans, has also partnered with CEPI, the University of Queensland, and Clover Biopharmaceuticals Inc., a Chinese biotechnology company, the same as Dynavax. Dynavax's stock is down 42% year-to-date. The S&P 500 has dropped 23%.
Pfizer stock is on a recent downswing in the wake of lackluster fourth-quarter earnings, though the company is partnering on a coronavirus vaccine. Is the pharma company a buy right now?
Glaxo's (GSK) long-acting injectable regimen of cabotegravir and rilpivirine gets its first approval for the treatment of HIV-1 infection in virologically-suppressed adults
This has been another tough pill to swallow: France’s health ministry has suggested that certain painkillers could aggravate the effects of the coronavirus. Olivier Veran tweeted last week that some nonsteroidal anti-inflammatories (aka NSAIDs) worsen the effects of COVID-19, the disease caused by the novel coronavirus. If you have a fever, take paracetamol [aka acetaminophen].
GlaxoSmithKline (GSK) is one of the ten largest pharmaceutical companies in the world; its particular strengths are in asthma/respiratory, HIV, and vaccines, observes Gavin Graham, contributing editor to Internet Wealth Builder.
Emma Walmsley has been the CEO of GlaxoSmithKline plc (LON:GSK) since 2017. This report will, first, examine the CEO...
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
The COVID-19 virus has sent the market and the global economy into a tailspin. The Organisation for Economic Co-operation and Development slashed its global growth forecast for 2020 Monday by 0.5 points to 2.5% versus already-weak 2.9% growth in 2019.Global banks have begun talking up the economy with the promise of stimulus injection.As the world and China in particular battle the deadly pandemic, a small batch of biotechs and a handful of big pharma companies are racing against time to bring to the market potential treatment and/or vaccines to combat the virus.Rocky R&D Pathway For Coronavirus Products Investors scurrying for cover amid the bloodbath in the stock market are investing in biotechs that are targeting the new coronavirus.COVID-19 levered biotechs are offering investors an opportunity due to the kind of returns the stocks can generate in the eventuality that R&D efforts come to fruition.Given that most of the investigational therapies are vaccines are only in the animal testing stage, is it too early to take a headlong plunge into these stocks?"Given the community spread in the U.S., particularly in the states of Washington and California, we believe the current administration's support for rapid development of vaccines and therapies in the U.S. could pave the way for an accelerated regulatory pathway to be made available by government agencies for the rapid market entry of such products that show conclusive efficacy against COVID-19," H.C. Wainwright analyst Raghuram Selvaraju said in a note.The analyst estimates it would take around 18-24 months to complete the clinical development of a COVID-19 vaccine.Benzinga reviewed the COVID-19-related updates from biotechs to gain an understanding of how close each is in bringing a treatment or vaccine to market. See Also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA DatesGilead: The Frontrunner? Large-cap biopharma Gilead Sciences, Inc.'s (NASDAQ: GILD) investigational drug remdesivir has the World Health Organization's seal of approval."There is only one drug right now that we think may have real efficacy and that's remdesivir," WHO assistant director-general Bruce Aylward said at a late February press briefing in China.Remdesivir is an investigational nucleotide analog with broad spectrum antiviral activity that has shown in vitro and in vivo activity in animal models against the viral pathogens MERS and SARS.Gilead has initiated two Phase 3 studies in adults diagnosed with COVID-19 following the FDA's rapid review and acceptance of the IND filed by the company.The company said it expects to enroll 1,000 patients at medical centers, mainly in Asia, beginning in March.Chinese health authorities have initiated two trials with remdesivir in infected patients in the Hubei province, and those clinical trial results are anticipated in April.The U.S. National Institute of Allergy and Infectious Diseases, or NIAID, has initiated a Phase 2 study to test remdesivir in hospitalized adult patients diagnosed with COVID-19.Inovio Sets Timeline Inovio Pharmaceuticals Inc (NASDAQ: INO) is working with Chinese contract development manufacturer Beijing Advaccine Biotechnology to develop INO-4800, a DNA vaccine for COVID-19, unveiled an accelerated development timeline.The company expects to commence a Phase 1 trial in April and mass produce the vaccine by the end of 2020 to be used in case of emergency or for further trials.One advantage of DNA vaccines is that they do not require refrigeration or cold chain logistics, according to H.C. Wainwright. Moderna's Vaccine Candidate To Enter Clinics Moderna Inc (NASDAQ: MRNA) said in late February it has shipped MRNA-1273, its mRNA vaccine targeting COVID-19, to the NIAID to be used in a Phase 1 study.H.C. Wainwright said Moderna could begin Phase 1 trials around the same time as Inovio.Novavax In Animal Testing Novavax, Inc. (NASDAQ: NVAX) said in late February that it is assessing multiple nanoparticle vaccine candidates in animal models to zero in on an optimal candidate for human testing.The company said it expects clinical trials to begin by the end of spring 2020. Vir Biotech Identifies Antivirals Vir Biotechnology Inc (NASDAQ: VIR) is working with WuXi Biologics on a COVID-19 treatment. The company said it has identified a number of monoclonal antibodies that bind to COVID-19 and is conducting research to determine if these can be effective as treatment and/or prophylaxis against the virus.Cocrystal Pharma Licenses Treatment Candidates Cocrystal Pharma Inc (NASDAQ: COCP) said Feb. 24 it has licensed from the Kansas State University Research Foundation antiviral compounds to treat norovirus and coronavirus infections. The company said it plans to pursue preclinical and clinical development of these compounds.NanoViricides Screens Compounds NanoViricides Inc (NYSE: NNVC) said in its fourth-quarter earnings release Feb. 24 it intends to perform initial testing of drug candidates for safety and effectiveness in cell culture studies in its own BSL-2 virology laboratory at its Shelton campus, using low-threat coronavirus strains.Vaxart's Vaccine Program Kicks Off Vaxart Inc (NASDAQ: VXRT) said in late January it has begun work on a program to develop an oral COVID-19 vaccine.The company said it plans to generate vaccine candidates based on the published genome of the coronavirus. Glaxo Lends Tech To Enhance Vaccine Efficiency GlaxoSmithKline plc (NYSE: GSK), though not developing a vaccine, has forged two tie-ups to aid COVID-19 vaccine research.The company announced a collaboration with the Coalition of Epidemic Preparedness Innovations, or CEPI, to provide its pandemic vaccine adjuvant vaccine technology to enhance the development of an effective vaccine against COVID-19.An adjuvant is added to vaccines to enhance its immune response. CEPI will work with Glaxo and entities funded by it that want to test their vaccine platform with Glaxo's adjuvant technology.Glaxo also announced Feb. 24 a research collaboration with Chinese biotech Clover for the latter's protein-based COVID-19 vaccine candidate S-Trimer, which is to be tested with the former's pandemic adjuvant system in preclinical studies.J&J, Sanofi Work With BARDA Johnson & Johnson (NYSE: JNJ) said in mid-February that its Janssen unit will work along with the Biomedical Advanced Research and Development Authority, or BARDA, on potential treatments for COVID-19.Janssen will work with the Belgium-based Rega Institute for Medical Research for screening potential compounds.The company said it is working with BARDA on a COVID-19 vaccine that will leverage its AdVac and PER.C6 technologies, which the company said will help rapidly upscale production of an optimal vaccine candidate.Sanofi SA (NASDAQ: SNY) also has a working relationship with BARDA to develop a COVID-19 vaccine using its recombinant DNA platform that it said will help produce an exact genetic match to proteins or antigenfound on the surface of the virus.This could be formulated to stimulate an immune response to protect against the virus, Sanofi said. Pfizer Joins The Race Pfizer Inc. (NYSE: PFE) reportedly said Monday it has identified some antiviral compounds from its development pipeline that could potentially treat COVID-19 infection.The pharma company said it plans to work with a third party to screen the compounds, with the results from the screening expected by the end of March. If they are found effective, Pfizer said it plans to begin clinical trials by the end of the year.The Race For COVID-19 Drugs Gilead as well as Moderna and Inovio could have an edge over the others, as Gilead's remdesivir is already in the clinics, while the latter two are set to start Phase 1 trials soon.Most others are still screening compounds or pursuing animal testing.The sell-side is guarded in its view regarding the value a potential therapy/vaccine could bring to its developer."Previous potential therapeutics for pandemics have failed to generate value in the medium-to-long term," Baird analyst Madhu Kumar said in a recent note.Photo courtesy of the CDC. Latest Ratings for GILD DateFirmActionFromTo Mar 2020RBC CapitalDowngradesTop PickOutperform Feb 2020DZ BankDowngradesBuyHold Feb 2020BarclaysInitiates Coverage OnUnderweight View More Analyst Ratings for GILD View the Latest Analyst Ratings See more from Benzinga * The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index * The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues * 4 Biotech Stocks Moving On COVID-19 Updates(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
A public-private partnership between ViiV Healthcare and UNC-Chapel Hill has been renewed – bringing another $20 million to Triangle researchers working to discover a cure for HIV.
GlaxoSmithKline PLC's unit ViiV Healthcare said on Monday its two-drug regimen to treat HIV was as effective in patients given the treatment every two months, as when administered once a month. The drug, Cabenuva, the long-acting injectable two-drug regimen of antiviral compounds cabotegravir and Johnson & Johnson's rilpivirine, met the main goal at the end of 48 weeks. "This two-drug regimen may provide an opportunity for people living with HIV to break the cycle of taking a daily pill and reduce their total treatment dosing days from 365 to six," Kimberly Smith, head of research and development, said.
One analyst has some out-of-the box ideas about drugs already on the market from Gilead Sciences, AbbieVie, and GlaxoSmithKline.
Germany's Merck KGaA said adjusted core earnings would see "strong" growth, excluding the effect of currency swings, driven by its prescription drugs unit and the lab equipment business. The company said that while the impact of the current coronavirus epidemic was difficult to determine, it was currently working on the assumption that the outbreak would reach its high point in the first quarter and subside during the second.